PEMAZYRE

Formula & Concentration

PEMAZYRE – pemigatinib 4.5 mg, 9 mg, and 13.5 mg tablet

Manufacturer

Incyte Corporation

Indications

myeloid/lymphoid neoplasm with FGFR1 rearrangement; cholangiocarcinoma with FGFR2 fusion or rearrangement

cholangiocarcinoma with FGFR2 fusion or rearrangement; myeloid/lymphoid neoplasm with FGFR1 rearrangement

Product Options

Package Size

NDC #

Presentation

4.5 MG

50881-0026-01

TABLET

9 MG

50881-0027-01

TABLET

13.5 MG

50881-0028-01

TABLET

Shelf Life and Storage

Controlled Room Temp (20-25°C)